Key result
An increased RAP/PCWP ratio was associated with a higher risk of death or hospitalization within 6 months in patients with advanced heart failure (HR 1.16; 95% CI 1-1.4; P<0.05).
Why the study?
Does an increased RAP/PCWP ratio predict adverse outcomes in patients with advanced heart failure?
Cohort
Does an increased RAP/PCWP ratio predict adverse outcomes in patients with advanced heart failure?
Hazard Ratio: 1.16 (95% CI 1–1.4)
p-value: p=<0.05
An increased RAP/PCWP ratio is associated with higher pulmonary vascular resistance, reduced RV function, and an increased risk of 6-month death or hospitalization in advanced heart failure.
No takes yet. Share an insight, caveat, or question.
Disproportionate RAP elevation signals RV dysfunction; leaves open whether ratio-guided therapy improves outcomes in advanced HF.
Drazner et al. (2013) conducted a cohort in Advanced heart failure. Increased RAP/PCWP ratio vs. Lower RAP/PCWP ratio tertiles was evaluated on 6-month death or hospitalization (HR 1.16, 95% CI 1-1.4, p=<0.05). An increased RAP/PCWP ratio was associated with a higher risk of death or hospitalization within 6 months in patients with advanced heart failure (HR 1.16; 95% CI 1-1.4; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: